CMP vs Fascia Iliaca Block

Complete Motor Sparing Protocol Versus Fascia Iliaca Suprainguinal Technique for Total Hip Arthroplasty, a Prospective Randomized Clinical Trial.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04426058

Enrollment

Registered

2020-06-11

Start date

2020-06-06

Completion date

2022-12-31

Last updated

2022-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative, Hip Arthroplasty

Keywords

Nerve Block, Fascia Iliaca Nerve Block, Complete Motor Sparing Protocol, Hip Arthroplasty, Pain control

Brief summary

Complete motorsparing protocol (CMP) has been developed to try to minimize the motor nerve block that is created when using Facia iliaca nerve block. The blocks performed in the (CMP) are the cluneal nerve block, Pericapsular nerve group block and lateral femoral cutaneous block. On the clinical trial, the investigators will randomize the participants that meet criteria to CMP or Fascia iliaca Block and compare the amount of opioid needed post op during 24 hours and their pain scores.

Interventions

DRUGCMP

Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml

DRUGFascia Illica

Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients ≥ 18 years old * Patients undergoing total hip arthroplasty posterior approach. * Patients willing to participate and sign informed consent

Exclusion criteria

* Severe COPD/other contraindication to general anesthesia that spinal would be more suitable. * Patient with a weight of less than 41 kg * Dementia, not alert or Oriented to person, place, or time * Chronic pain patient with daily opioid use at home. * Patient with allergy to local anesthetics * Patient refusal * Total hip arthroplasty revision * Concomitant pain in different area from operative site. * Pregnancy * Patient with active infection on the injection sites for the blocks * Patients unable or willing to understand or comply with the study protocol

Design outcomes

Primary

Measure	Time frame	Description
Measurement of opioid use	24 hours	Measurement of opioid use (mg) for pain control after surgery once patient in recovery area

Secondary

Measure	Time frame	Description
Measurement of the pain control	24 hours	Measurement of the pain control via numeric rating scale 0-10 where 0 is no pain and 10 is the worst pain.

Countries

United States

Contacts

Primary ContactCarlos Martinez Parra, MD

carlos.martinezparra@lumc.edu(708) 216-6462

Backup ContactMichael Majewski, MD

mimajewski@lumc.edu(708) 216-6462

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026